Maternal endothelin-1 is elevated and correlates with the severity of blood pressure elevation in preeclampsia. The endothelin-1 is likely released from the maternal endothelium. Presence of T allele at 5665 position in maternal EDN1 gene is associated with higher endothelin-1 levels. Placental endothelin-1 synthesis is reduced in preeclampsia. The combination of elevated maternal and reduced placental endothelin-1 may be an adaptive response to reduced uteroplacental flow in preeclampsia.
http://www.ncbi.nlm.nih.gov/pubmed/19730395
Read in conjunction with the [url="http://www.preeclampsia.org/forum/viewtopic.php?t=36499"]study about 17-p[/url] that I just posted, this illustrates pretty nicely what we're up against here. First: it's genetic. Second: it's adaptive, and blocking it might not be the best idea. When there's not enough bloodflow into the placenta, doing things that lower the maternal blood pressure has the potential to compromise the placental perfusion, and thus the baby. This is why we have [url="http://www.smfm.org"]maternal-fetal medicine specialists[/url] to balance the competing demands of mother and baby -- delivery and blood pressure control are always appropriate therapy for the mother, but not for the baby -- and why this is such a difficult disease to treat or cure.
Information provided on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disorder, or prescribing any medication. The Preeclampsia Foundation presents all data as is, without any warranty of any kind, express or implied, and is not liable for its accuracy, for mistakes or omissions of any kind, nor for any loss or damage caused by a user's reliance on information obtained on the site. Professional opinions on this condition vary greatly. The Preeclampsia Foundation endorses no one course of treatment or "cure".
